Chimeric Therapeutics (ASX:CHM) Total Operating Expense: A$13.31 Mil (TTM As of Dec. 2025)


What is Chimeric Therapeutics Total Operating Expense?

Chimeric Therapeutics ASX:CHM -1.69% Total Operating Expense is A$13.31 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Chimeric Therapeutics's Total Operating Expense for the six months ended in Dec. 2025 was A$3.76 Mil. Chimeric Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$13.31 Mil.

Chimeric Therapeutics Total Operating Expense Related Terms

Chimeric Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Chimeric Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chimeric Therapeutics Total Operating Expense Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Total Operating Expense
15.69 17.19 29.49 21.02 18.23

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.04 11.98 8.68 9.56 3.76

Chimeric Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$13.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of A$13.31 Mil mean?
Chimeric Therapeutics (ASX:CHM) has a Total Operating Expense of A$13.31 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Chimeric Therapeutics and its competitors.
Is Chimeric Therapeutics' Total Operating Expense too high?
Chimeric Therapeutics' current Total Operating Expense is A$13.31 Mil.
How does Chimeric Therapeutics' Total Operating Expense compare to VRTX and REGN?
Chimeric Therapeutics' Total Operating Expense of A$13.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Chimeric Therapeutics and its competitors. Chimeric Therapeutics's current Total Operating Expense is A$13.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (ASX:CHM) has a current Total Operating Expense of A$13.31 Mil. The current Total Operating Expense is A$13.31 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Chimeric Therapeutics (ASX:CHM), the current Total Operating Expense is A$13.31 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chimeric Therapeutics Business Description

Address 62 Lygon Street, Level 3, Carlton, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.